Sign in
Active, not recruitingNo phase

Beating Heart Mitral Valve Repair With the HARPOON™ System

Key facts

Who runs it
Edwards Lifesciences
Where
Ann Arbor, Atlanta, Baltimore, Murray, Nashville, Portland, Rochester, and San Francisco, United StatesSee the 9 sites
Trial code
Status
Active, not recruiting
People taking part
25 people enrolled
Started
16 Dec 2020
Expected to end
20 Dec 2027
Type of study
Interventional
Treatments tested
  • HARPOON™ Beating Heart Mitral Valve Repair System
Record updated
19 August 2026

Who can take part

Age
21 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (40)Hide the full registry criteria

Who can take part

  • Each subject is required to meet all of the following inclusion criteria:
  • Patient is >/= 21 years old
  • Presence of severe degenerative mitral regurgitation with mid-segment posterior leaflet prolapse (without commissural involvement) by echocardiographic study
  • Mitral leaflet coaptation surface sufficient to reduce mitral regurgitation without undue leaflet tension, based on the judgment of the Echocardiographic Core Lab
  • Patient competent to sign informed consent and able to return for follow-up and is capable of participating in all testing associated with this clinical investigation

Who cannot take part

  • Have undergone cardiac or peripheral vascular procedures within 30 days prior to the trial procedure
  • Requirement for concomitant cardiac surgery
  • Previous structural heart intervention (e.g. any heart valve replacement or repair procedures). Previous percutaneous coronary intervention (PCI) is allowed
  • Previous coronary artery bypass grafting (CABG)
  • Stroke within 30 days prior to index procedure
  • ST segment elevation myocardial infarction (STEMI) requiring intervention within 30 days prior to index procedure
  • Active SARS-CoV-2 infection (Coronavirus-19 [COVID-19]) or previously diagnosed with COVID-19 with sequelae that could confound endpoint assessments (as assessed by Case Review Committee)
  • Planned treatment with any other investigational device or procedure through 1-year follow-up, or who are currently participating in an investigational drug or device trial
  • Concurrent medical condition with a life expectancy of less than 12 months in the judgment of the Investigator
  • Planned cardiac or peripheral vascular procedures within 30 days after the trial procedure
  • Severe pulmonary hypertension (pulmonary artery systolic pressure > 60mmHg)
  • Severe aortic stenosis or insufficiency
  • Any history of endocarditis
  • Contraindication to cardiac surgery, including hostile chest or history of mediastinal radiation
  • Evidence of cirrhosis or hepatic synthetic failure (Child-Pugh Class B or higher, [or MELD score of ≥ 13])
  • Rheumatic heart disease including rheumatic mitral stenosis
  • Condition or conditions that, in the opinion of the Investigator, precludes participation, including willingness to comply with all follow-up procedures
  • Contraindication for transesophageal echocardiography (TEE), including esophageal spasm, esophageal stricture, esophageal laceration, esophageal perforation, esophageal diverticula (e.g. Zenker's diverticulum)
  • Left ventricular ejection fraction (LVEF) <30%, or severely impaired right ventricular dysfunction as measured by the core lab
  • Renal insufficiency CKD Stage 3b or worse (GFR < 45 ml/min/1.73 m2)
  • History of bleeding diathesis or coagulopathy or leukopenia (WBC < 3000 mcL) or acute anemia (Hb < 9 g/dL) or thrombocytopenia (platelets < 50,000 cells mcL)
  • Pregnant or lactating at the time of enrollment (women of childbearing age should have negative pregnancy test within 72 hours of surgery) or planning pregnancy within the next 12 months
  • Patients will be excluded if ANY of the following criteria apply:
  • Functional mitral regurgitation (FMR)
  • Evidence of anterior or bileaflet prolapse
  • Severe mitral annular calcification (MAC)
  • Moderate or greater leaflet calcification
  • Fragile or thinning apex (e.g. LV aneurysm)
  • Severe tricuspid regurgitation. (Patients with mild or moderate tricuspid regurgitation are not excluded.)
  • Hemodynamic instability or cardiogenic shock at the time of enrollment (e.g. requiring inotropic support or mechanical support devices)
  • Refuse blood products
  • Carotid stenosis ≥ to 80% at time of enrollment
  • Echocardiographic evidence of intracardiac mass (e.g. left ventricular, atrial, or appendage thrombus, myxoma, or vegetation)
  • Cannot tolerate procedural anticoagulation or post-procedure antiplatelet regimen; Intra-operative exclusion criteria
  • No longer meets eligibility criteria based on intra-operative assessment

Where in United States

  • University of Michigan Health SystemAnn Arbor, United States
  • Piedmont Heart InstituteAtlanta, United States
  • Johns HopkinsBaltimore, United States
  • University of Maryland Medical CenterBaltimore, United States
  • Intermountain Heart InstituteMurray, United States
  • Centennial Medical CenterNashville, United States
  • OHSU Knight Cardiovascular InstitutePortland, United States
  • Mayo ClinicRochester, United States
  • UCSFSan Francisco, United States

About the trial

What the trial wants to find out

The objective of the study is to evaluate the safety and effectiveness of the HARPOON™ System in the treatment of patients with severe degenerative mitral regurgitation (DMR).

The group in the trial

  • HARPOON™ Beating Heart Mitral Valve Repair SystemTreatment being tested

    Subjects who were treated with the HARPOON™ Beating Heart Mitral Valve Repair System

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Prospective, Multi-center Trial to Evaluate the Safety and Effectiveness of Beating Heart Mitral Valve Repair With the HARPOON™ System (RESTORE)
Record updated
19 August 2026